House passes bill to reauthorize FDA user fee programs

The House yesterday voted 392-28 to pass legislation (H.R. 7667) that would reauthorize Food and Drug Administration user fee programs, which provide funding for the agency to review drugs, devices and biologics. Among other provisions, the bipartisan bill would include drugs on the FDA’s shortages list in a pilot program to designate advanced manufacturing technologies. The Senate Health, Education, Labor, and Pensions Committee will mark up their version of the bill Tuesday.